A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of ART‐001 with a novel oral pediatric formulation in healthy subjects

ART‐001 is an orally available selective PI3Kα inhibitor currently being developed for the treatment of slow‐flow vascular malformations (SFVMs). ART‐001 used to be developed for advanced solid tumors, but was suspended largely due to significant pharmacokinetic (PK) variability in its phase I studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Akira, Uemura, Naoto, Kuniyeda, Kanako, Ando, Haruhi, Higashi, Toshinori, Nagabukuro, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582665/
https://www.ncbi.nlm.nih.gov/pubmed/37606073
http://dx.doi.org/10.1111/cts.13597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582665/
https://www.ncbi.nlm.nih.gov/pubmed/37606073
http://dx.doi.org/10.1111/cts.13597

Ejemplares similares